DENVER -- (BUSINESS WIRE) -- Corgenix Medical Corporation (OTC BB: CONX.OB) announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio™ Assay. The TxBCardio test measures urinary levels of the thromboxane metabolite 11dhTxB2 to determine aspirin effect in apparently healthy individuals. CE mark designation enables commercial marketing and distribution of the product in Europe.
The TxBCardio automated immunoturbidimetric (IT) assay format enables testing for urinary 11dhTxB2, the thromboxane metabolite measured by the AspirinWorks™ Test (ELISA assay), to be run on clinical chemistry platforms for higher-volume laboratories and in hospitals. The AspirinWorks Test is a simple urine test that measures levels of 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. The AspirinWorks Test was FDA-cleared in the U.S. in 2007; the TxBCardio brand was established to better emphasize the importance of the thromboxane biomarker while expanding into new products and technologies. The AspirinWorks ELISA assay continues to be sold worldwide.
“Achieving CE Mark is a significant milestone in our collaborative development efforts with Randox for thromboxane testing,” said Douglass Simpson, Corgenix President and CEO. “We’re also moving forward with our strategic partner and master distributor, the ELITech Group, to expand global coverage of this new assay and broaden application onto additional platforms.”
The TxBCardio assay will be manufactured at Randox Laboratories in the United Kingdom. Both Corgenix Medical and Randox Laboratories will be selling the new test worldwide under the TxBCardio brand name.
The safety and efficacy of the TxBCardio assay has not yet been evaluated by the FDA and therefore is not cleared for clinical diagnostic use in the United States.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.